Form 4: Unicycive Therapeutics EVP Granted 10,000 Stock Options

Douglas Jermasek, EVP of Corporate Strategy at Unicycive Therapeutics, Inc., was granted 10,000 stock options with an exercise price of $4.71.

Summary

• Douglas Jermasek, the Executive Vice President of Corporate Strategy at Unicycive Therapeutics, Inc. (UNCY), was granted 10,000 stock options.
• The options have an exercise price of $4.71 per share.
• The grant date for these options was July 28, 2025.
• The options are set to expire on July 28, 2035.
• The vesting schedule dictates that 2,500 of the options will vest on the first anniversary of the grant date, with the remaining options vesting at a rate of 1/36th per month thereafter.
• Following this transaction, Douglas Jermasek beneficially owns 215,500 derivative securities.

Sentiment

Score: 6

Explanation: The filing indicates a standard executive compensation event, which is generally neutral to slightly positive as it aligns management incentives with shareholder interests. It does not contain significant new financial or operational information.

Positives

• The grant of stock options aligns the executive's incentives with shareholder value creation, as the options gain value if the stock price increases above the exercise price.
• The vesting schedule encourages long-term commitment and performance from the EVP of Corporate Strategy.

Future Outlook

The vesting schedule for the granted stock options extends over time, indicating a future alignment of the executive's compensation with the company's long-term performance.

Industry Context

This filing represents a routine executive compensation event within the biotechnology or pharmaceutical industry, where stock options are a common component of incentive-based pay for key personnel.

Comparison to Industry Standards

• The grant of stock options to an EVP is a standard practice in the biotechnology and pharmaceutical sectors, aligning executive incentives with company performance.
• The vesting schedule, with an initial cliff and subsequent monthly vesting, is a common structure designed to retain talent and encourage long-term commitment, comparable to practices at companies like Moderna or BioNTech for their executives.

Stakeholder Impact

• Shareholders: The grant of options can be seen as a positive for shareholders as it aligns the executive's financial interests with the company's stock performance. However, it also represents potential future dilution if options are exercised.
• Employees (specifically Douglas Jermasek): Directly benefits from the potential for future equity gains based on company performance.

Next Steps

• 2,500 of the granted stock options will vest on July 28, 2026.
• The remaining options will vest at a rate of 1/36th per month after the first anniversary.

Key Dates

Keywords

Unicycive Therapeutics, UNCY, Stock Options, Executive Compensation, SEC Form 4, Insider Transaction, Derivative Securities, Vesting Schedule